<DOC>
	<DOCNO>NCT01281306</DOCNO>
	<brief_summary>The purpose study evaluate dose response blood pressure lower 4 dos AHU377 , give daily ( 50 mg , 100 mg , 200 mg 400 mg ) combination fix dose valsartan ( 320 mg ) .</brief_summary>
	<brief_title>An 8-week Study Evaluate Dose Response AHU377 Combination With Valsartan 320 mg Patients With Mild-to-moderate Systolic Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Written informed consent must obtain assessment perform . Patients mildtomoderate systolic hypertension , untreated currently take antihypertensive therapy . Ability communicate comply study requirement demonstrate good medication compliance ( â‰¥ 80 % compliance rate ) runin period . Severe hypertension History angioedema , drugrelated otherwise , report patient . Pregnant nursing ( lactate ) woman . Women childbearing potential ( WOCBP ) , UNLESS use adequate birth control method . History evidence secondary form hypertension . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>hypertension</keyword>
	<keyword>blood pressure</keyword>
	<keyword>LCZ696</keyword>
	<keyword>dual-acting</keyword>
	<keyword>neprilysin</keyword>
	<keyword>nep inhibitor</keyword>
	<keyword>vasopeptidase</keyword>
	<keyword>angiotensin receptor</keyword>
	<keyword>angiotensin receptor neprilysin inhibitor ( ARNi )</keyword>
</DOC>